並列摘要
Patients under hemodialysis are at increased risk of acquiring HBV infection. The risk has come down considerably in Western countries following the introduction of universal immunization and strict isolation practices, but remains substantial in developing countries. Viral replication is accelerated following introduction of immunosuppression in kidney transplant recipients. A number of studies have shown that HBV infection increases the risk of mortality, most often due to liver disease and graft failure. Effective antiviral therapy permits inhibition of viral replication and retards development of progressive liver disease, and may lower the risk of liver cancer. KDIGO guideline offered practical and important suggestions to HBV infected patients according to current evidences.